# Finasteride Treatment of Severe Nodulocystic Acne

> **NCT02502669** · PHASE2 · COMPLETED · sponsor: **Elorac, Inc.** · enrollment: 106 (actual)

## Conditions studied

- NODULOCYSTIC ACNE

## Interventions

- **DRUG:** Finasteride 23.5 mg tablets
- **DRUG:** Finasteride 33.5 mg tablets
- **DRUG:** Placebo tablets

## Key facts

- **NCT ID:** NCT02502669
- **Lead sponsor:** Elorac, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-06-06
- **Final completion:** 2017-06-06
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02502669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02502669, "Finasteride Treatment of Severe Nodulocystic Acne". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02502669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*